Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016561 · ClinicalTrials.gov registry record · NA
Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01016561 is a NA study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants.
The verdict
NCT01016561, a NA study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy.
Interventions
- RADIATION intensity-modulated radiation therapy
- RADIATION 3-dimensional conformal radiation therapy
- RADIATION external beam radiation therapy
- RADIATION intracavitary balloon brachytherapy
- RADIATION radiation therapy treatment planning/simulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016561
The ClinicalTrials.gov registry entry for NCT01016561 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT01016561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01016561 about?
NCT01016561 is a clinical study titled "Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer". Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor c...
What is the current status of trial NCT01016561?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2009-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01016561?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), 3-dimensional conformal radiation therapy (RADIATION), external beam radiation therapy (RADIATION), intracavitary balloon brachytherapy (RADIATION), radiation therapy treatment planning/simulation (RADIATION).
Who is sponsoring clinical trial NCT01016561?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.